| Literature DB >> 9878184 |
T Brenner1, E Poradosu, D Soffer, C Sicsic, A Gazit, A Levitzki.
Abstract
Tyrosine kinase blockers from the AG 126/AG-556 tyrphostin family are shown to inhibit the lipopolysaccharide (LPS)-induced production of tumor necrosis factor alpha (TNFalpha), nitric oxide (NO), and prostaglandin E2 (PGE2) in primary rat astrocytes cultures. The tyrphostin AG-556 which was previously shown to be effective against sepsis in mice and dogs also show excellent efficacy in inhibiting experimental autoimmune encephalomyelitis (EAE) in mice. AG-556 does not block the activation of JNK/SAPK and of p38/HOG and therefore seems to act at a target down stream to these kinases which is activated in stress or at a target on an obligatory parallel pathway. These findings together with previous results showing inhibition of sepsis in mice and dogs suggest that protein tyrosine kinase (PTK) blockers of the AG-556 family may be considered in the management of human autoimmune disorders such as multiple sclerosis (MS). Copyright 1998 Academic Press.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9878184 DOI: 10.1006/exnr.1998.6971
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.330